Boundless Bio is reducing workforce by one-third and focusing on combination therapy, aiming for innovation.

From Nasdaq: 2025-05-23 17:51:00

Boundless Bio (BOLD) plans to reduce its workforce by one-third to streamline operations. It will discontinue certain arms of the BBI-355 trial and focus on a combination therapy with BBI-825. President Zachary Hornby expressed commitment to innovative therapies for oncogene-amplified cancers. The company’s cash, cash equivalents, and investments of $138.3 million as of March 31, 2025, will support operations until the first half of 2028. Portfolio prioritization and streamlined operations aim to achieve clinical milestones for therapeutic programs. This strategic shift aims to develop impactful medicines with current resources.



Read more at Nasdaq: Boundless Bio To Reduce Its Workforce By About One-third